The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Guidelines of care for the management of atopic dermatitis
Open accessAbstract
Atopic dermatitis (AD) is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of four sections, treatment of AD with non-pharmacological interventions and pharmacological topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse effects of topical glucocorticosteroids
Hengge, U. R., Ruzicka, T., Schwartz, R. A., & Cork, M. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.01.010 · Cited by 1,151
Systematic review of treatments for atopic eczema.
Hoare, Po, L. W., & Williams (2000) · Health Technology Assessment · doi:10.3310/hta4370 · Cited by 794
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Topical corticosteroid phobia in patients with atopic eczema: CORTICOSTEROID PHOBIA IN ATOPIC ECZEMA
Charman, C. R., Morris, A. D., & Williams, H. C. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03473.x · Cited by 590
Self-citationEbell, M. H., Siwek, J., Weiss, B. D., Woolf, S. H., Susman, J., Ewigman, B., & Bowman, M. (2004) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.17.1.59 · Cited by 561
Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity
Huang, J. T., Abrams, M., Tlougan, B., Rademaker, A., & Paller, A. S. (2009) · Pediatrics · doi:10.1542/peds.2008-2217 · Cited by 481
Self-citationChamlin, S. (2002) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(02)00048-8 · Cited by 449
Self-citationAtopic dermatitis: A practice parameter update 2012
Schneider, L., Tilles, S., Lio, P., Boguniewicz, M., Beck, L., LeBovidge, J., Novak, N., Bernstein, D., Blessing-Moore, J., Khan, D., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.672 · Cited by 417
Wahn, U., Bos, J. D., Goodfield, M., Caputo, R., Papp, K., Manjra, A., Dobozy, A., Paul, C., Molloy, S., Hultsch, T., et al. (2002) · Pediatrics · doi:10.1542/peds.110.1.e2 · Cited by 404
Guidelines of care for atopic dermatitis
Hanifin, J. M., Cooper, K. D., Ho, V. C., Kang, S., Krafchik, B. R., Margolis, D. J., Schachner, L. A., Sidbury, R., Whitmore, S. E., Sieck, C. K., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.08.003 · Cited by 387
Self-citation
Cited by
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationDe Pessemier, B., Grine, L., Debaere, M., Maes, A., Paetzold, B., & Callewaert, C. (2021) · Microorganisms · doi:10.3390/microorganisms9020353 · Cited by 628
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationPaller, A. S., Tom, W. L., Lebwohl, M. G., Blumenthal, R. L., Boguniewicz, M., Call, R. S., Eichenfield, L. F., Forsha, D. W., Rees, W. C., Simpson, E. L., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.05.046 · Cited by 577
Self-citationThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Self-citationDysbiosis and Staphylococcus aureus Colonization Drives Inflammation in Atopic Dermatitis
Kobayashi, T., Glatz, M., Horiuchi, K., Kawasaki, H., Akiyama, H., Kaplan, D. H., Kong, H. H., Amagai, M., & Nagao, K. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.014 · Cited by 545
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., et al. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.3023 · Cited by 516
Self-citationde Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
Reich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00589-4 · Cited by 402
JAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
Self-citationSimpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18898 · Cited by 396
Self-citationTrial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917006 · Cited by 361
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C.-Y., Liu, Z., Gontijo Lima, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206714 · Cited by 345
Self-citationThe Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review
Purnamawati, S., Indrastuti, N., Danarti, R., & Saefudin, T. (2017) · Clinical Medicine & Research · doi:10.3121/cmr.2017.1363 · Cited by 340
Simpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.017 · Cited by 331
Self-citationFirst-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis
Myles, I. A., Earland, N. J., Anderson, E. D., Moore, I. N., Kieh, M. D., Williams, K. W., Saleem, A., Fontecilla, N. M., Welch, P. A., Darnell, D. A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120608 · Cited by 326
Silverberg, J. I., Toth, D., Bieber, T., Alexis, A. F., Elewski, B. E., Pink, A. E., Hijnen, D., Jensen, T. N., Bang, B., Olsen, C. K., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19573 · Cited by 326
Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection
Fishbein, A. B., Silverberg, J. I., Wilson, E. J., & Ong, P. Y. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.06.044 · Cited by 321
Papp, K., Szepietowski, J. C., Kircik, L., Toth, D., Eichenfield, L. F., Leung, D. Y. M., Forman, S. B., Venturanza, M. E., Sun, K., Kuligowski, M. E., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.04.085 · Cited by 313
Self-citationA Survey of the Structures of US FDA Approved Combination Drugs
Das, P., Delost, M. D., Qureshi, M. H., Smith, D. T., & Njardarson, J. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01610 · Cited by 312
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L., Guttman-Yassky, E., Ong, P. Y., Silverberg, J., & Farrar, J. R. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 305
Reich, K., Kabashima, K., Peris, K., Silverberg, J. I., Eichenfield, L. F., Bieber, T., Kaszuba, A., Kolodsick, J., Yang, F. E., Gamalo, M., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.3260 · Cited by 285
Self-citationEmollients and moisturisers for eczema
van Zuuren, E. J., Fedorowicz, Z., Christensen, R., Lavrijsen, A. P., & Arents, B. W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012119.pub2 · Cited by 260
Deleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.074 · Cited by 255
Kabashima, K., Furue, M., Hanifin, J. M., Pulka, G., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Nakano, M., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.018 · Cited by 248
Self-citationTreatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Kim, B. S., Howell, M. D., Sun, K., Papp, K., Nasir, A., & Kuligowski, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.042 · Cited by 226
Eichenfield, L. F., Ahluwalia, J., Waldman, A., Borok, J., Udkoff, J., & Boguniewicz, M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.009 · Cited by 204
“Source: Eichenfield et al.(2) J ALLERGY CLIN IMMUNOL”
BackgroundInfluentialSelf-citationUnmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01291-2 · Cited by 126
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
Simpson, E. L., Imafuku, S., Poulin, Y., Ungar, B., Zhou, L., Malik, K., Wen, H.-C., Xu, H., Estrada, Y. D., Peng, X., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.043 · Cited by 120
Self-citationA Comprehensive Review of the Treatment of Atopic Eczema
Lee, J. H., Son, S. W., & Cho, S. H. (2016) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2016.8.3.181 · Cited by 112
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Murata, R., Kaino, H., & Nagata, T. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15173 · Cited by 105
Jiang, W., Ni, B., Liu, Z., Liu, X., Xie, W., Wu, I. X. Y., & Li, X. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00410-6 · Cited by 91
Xu, S., Kwa, M., Lohman, M. E., Evers-Meltzer, R., & Silverberg, J. I. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.3046 · Cited by 90
González‐López, G., Ceballos‐Rodríguez, R. M., González‐López, J. J., Feito Rodríguez, M., & Herranz‐Pinto, P. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15165 · Cited by 66
Gustafson, E., Pacheco, J., Wehbe, F., Silverberg, J., & Thompson, W. (2017) · 2017 IEEE International Conference on Healthcare Informatics (ICHI) · doi:10.1109/ichi.2017.31 · Cited by 65
“During this chart review (completed December 2015), the reviewers documented the presence of each of the Hanifin and Rajka (HR) major and minor criteria [14] and UK Working Party (UKWP) criteria [15] (see below), along with other information not relevant to the current study.”
BackgroundMethodInfluentialDiagnosis and Management of Dermatitis, Including Atopic, Contact, and Hand Eczemas
Chan, C. X., & Zug, K. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.04.003 · Cited by 48
Abdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Bernardo, D., Bieber, T., & Torres, T. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00793-5 · Cited by 43
The evolving atopic dermatitis management landscape
Sahni, V. N., Balogh, E. A., Strowd, L. C., & Feldman, S. R. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999412 · Cited by 20
Self-citationThe role of lebrikizumab in the treatment of atopic dermatitis in the adult population
Prajapati, S., Fardos, M., Desai, A. D., & Feldman, S. R. (2023) · Immunotherapy · doi:10.2217/imt-2023-0066 · Cited by 4
Metadata
- Authors
- Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., Cordoro, K. M., Davis, D. M., Feldman, S. R., Hanifin, J. M., Margolis, D. J., Silverman, R. A., Simpson, E. L., Williams, H. C., Elmets, C. A., Block, J., Harrod, C. G., Begolka, W. S., & Sidbury, R.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 71
- Issue
- 1
- Pages
- 116-132
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2142327072
- Cited by
- 1,224
- References
- 111
- FWCI
- 76.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.